COVID-19 reinfection in a healthcare worker after exposure with high dose of virus: A case report

Evaluation of possible COVID-19 reinfection in children: A multicenter clinical study

BACKGROUND

Although it was originally unknown whether there would be cases of reinfection of coronavirus disease 2019 (COVID-19) as seen with other coronaviruses, cases of reinfection were reported from various regions recently. However, there is little information about reinfection in children.

METHODS

In this study, we aimed to investigate the incidence and clinical findings of reinfection in pediatric patients who had recovered from COVID-19. We retrospectively evaluated all patients under 18 years of age with COVID-19 infection from a total of eight healthcare facilities in Turkey, between March 2020 and July 2021. Possible reinfection was defined as a record of confirmed COVID-19 infection based on positive reverse transcription-polymerase chain reaction (RT-PCR) test results at least 3 months apart.

RESULTS

A possible reinfection was detected in 11 out of 8840 children, which yielded an incidence of 0.12%. The median duration between two episodes of COVID-19 was 196 (92-483) days. When initial and second episodes were compared, the rates of symptomatic and asymptomatic disease were similar for both, as was the severity of the disease (p = 1.000). Also, there was no significant difference in duration of symptoms (p = 0.498) or in hospitalization rates (p = 1.000). Only one patient died 15 days after PCR positivity, which resulted in a 9.1% mortality rate for cases of reinfection in pediatric patients.

CONCLUSION

We observed that children with COVID-19 were less likely to be exposed to reinfection when compared with adults. Although the clinical spectrum of reinfection was mostly similar to the first episode, we reported death of a healthy child during the reinfection.

The impact of a power law-induced memory effect on the SARS-CoV-2 transmission

It is well established that COVID-19 incidence data follows some power law growth pattern. Therefore, it is natural to believe that the COVID-19 transmission process follows some power law. However, we found no existing model on COVID-19 with a power law effect only in the disease transmission process. Inevitably, it is not clear how this power law effect in disease transmission can influence multiple COVID-19 waves in a location. In this context, we developed a completely new COVID-19 model where a force of infection function in disease transmission follows some power law. Furthermore, different realistic epidemiological scenarios like imperfect social distancing among home-quarantined individuals, disease awareness, vaccination, treatment, and possible reinfection of the recovered population are also considered in the model. Applying some recent techniques, we showed that the proposed system converted to a COVID-19 model with fractional order disease transmission, where order of the fractional derivative ( α ) in the force of infection function represents the memory effect in disease transmission. We studied some mathematical properties of this newly formulated model and determined the basic reproduction number (R 0 ). Furthermore, we estimated several epidemiological parameters of the newly developed fractional order model (including memory index α ) by fitting the model to the daily reported COVID-19 cases from Russia, South Africa, UK, and USA, respectively, for the time period March 01, 2020, till December 01, 2021. Variance-based Sobol's global sensitivity analysis technique is used to measure the effect of different important model parameters (including α ) on the number of COVID-19 waves in a location (W C ). Our findings suggest that α along with the average transmission rate of the undetected (symptomatic and asymptomatic) cases in the community (β 1 ) are mainly influencing multiple COVID-19 waves in those four locations. Numerically, we identified the regions in the parameter space of α andβ 1 for which multiple COVID-19 waves are occurring in those four locations. Furthermore, our findings suggested that increasing memory effect in disease transmission ( α → 0) may decrease the possibility of multiple COVID-19 waves and as well as reduce the severity of disease transmission in those four locations. Based on all the results, we try to identify a few non-pharmaceutical control strategies that may reduce the risk of further SARS-CoV-2 waves in Russia, South Africa, UK, and USA, respectively.

Detection of multiple waves for COVID-19 and its optimal control through media awareness and vaccination: study based on some Indian states

COVID-19 is a highly infectious disease, and in very recent times, it has shown a massive impact throughout the globe. Several countries faced the COVID-19 infection waves multiple times. These later waves are more aggressive than the first wave and drastically impact social and economic factors. We developed a mechanistic model with imperfect lockdown effect, reinfection, transmission variability between symptomatic & asymptomatic, and media awareness to focus on the early detection of multiple waves and their control measures. Using daily COVID-19 cases data from six states of India, we estimated several important model parameters. Moreover, we estimated the home quarantine, community, and basic reproduction numbers. We developed an algorithm to carry out global sensitivity analysis (Sobol) of the parameters that influence the number of COVID-19 waves ( W C ) and the average number of COVID-19 cases in a wave ( A W ). We have identified some critical controlling parameters that mainly influenced W C and A W . Our study also revealed the best COVID-19 control strategy/strategies among vaccination, media awareness, and their combination using an optimal cost-effective study. The detailed analysis suggests that the severity of asymptomatic transmission is around 10% to 29% of that of symptomatic transmission in all six locations. About 1% to 4% of the total population under lockdown may contribute to new COVID-19 infection in all six locations. Optimal cost-effective analysis based on interventions, namely only vaccination (VA), only media awareness (ME), and a combination of vaccination & media (VA+ME), are projected for the period March 14, 2020, to August 31, 2021, for all the six locations. We have found that a large percentage of the population (26% to 45%) must be vaccinated from February 13 to August 31, 2021, to avert an optimal number of COVID-19 cases in these six locations.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s11071-022-07887-5.

SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria

BACKGROUND

The COVID-19 pandemic has had a devastating impact on the world over the past two years (2020-2021). One of the key questions about its future trajectory is the protection from subsequent infections and disease conferred by a previous infection, as the SARS-CoV-2 virus belongs to the coronaviruses, a group of viruses the members of which are known for their ability to reinfect convalescent individuals. Bulgaria, with high rates of previous infections combined with low vaccination rates and an elderly population, presents a somewhat unique context to study this question.

METHODS

We use detailed governmental data on registered COVID-19 cases to evaluate the incidence and outcomes of COVID-19 reinfections in Bulgaria in the period between March 2020 and early December 2021.

RESULTS

For the period analyzed, a total of 4,106 cases of individuals infected more than once were observed, including 31 cases of three infections and one of four infections. The number of reinfections increased dramatically during the Delta variant-driven wave of the pandemic towards the end of 2021. We observe a moderate reduction of severe outcomes (hospitalization and death) in reinfections relative to primary infections, and a more substantial reduction of severe outcomes in breakthrough infections in vaccinated individuals.

CONCLUSIONS

In the available datasets from Bulgaria, prior infection appears to provide some protection from severe outcomes, but to a lower degree than the reduction in severity of breakthrough infections in the vaccinated compared to primary infections in the unvaccinated.

SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: a case report

The COVID-19 pandemic has severely affected the entire globe since the first isolation of SARS-CoV-2 from patients with severe respiratory illness in Wuhan, China. Although the global vaccination drive is in full swing, many cases of reinfection have also been reported after vaccination. Currently, there is a scarcity of data available on the reinfection and vaccine breakthrough infections in Iraq. In this letter, we have presented a case report on the SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker after completion of the double-dose vaccination. An increased symptom severity was reported on the second infection, which was confirmed to be of Delta variant. Such vaccine breakthrough infection reports have raised important questions regarding the duration of vaccine-mediated immunity and vaccine effectiveness against all circulating variants. These have further emphasized the importance of following non-pharmaceutical interventions by fully vaccinated individuals, especially at health-care settings.

COVID-19 reinfection in Liberia: Implication for improving disease surveillance

COVID-19 remains a serious disruption to human health, social, and economic existence. Reinfection with the virus intensifies fears and raises more questions among countries, with few documented reports. This study investigated cases of COVID-19 reinfection using patients’ laboratory test results between March 2020 and July 2021 in Liberia. Data obtained from Liberia’s Ministry of Health COVID-19 surveillance was analyzed in Excel 365 and ArcGIS Pro 2.8.2. Results showed that with a median interval of 200 days (Range: 99–415), 13 out of 5,459 cases were identified and characterized as reinfection in three counties during the country’s third wave of the outbreak. Eighty-six percent of the COVID-19 reinfection cases occurred in Montserrado County within high clusters, which accounted for over 80% of the randomly distributed cases in Liberia. More cases of reinfection occurred among international travelers within populations with high community transmissions. This study suggests the need for continued public education and surveillance to encourage longer-term COVID-19 preventive practices even after recovery.

Clinical and Epidemiological Characteristics of COVID-19 Patients with SARS-CoV-2 Re-Detected on PCR Test after Discharge from Isolation

There have been multiple reports of patients with coronavirus disease (COVID-19) testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after discharge; however, information on the characteristics of such cases is limited. In this case report, we aimed to identify clinical and epidemiological characteristics of patients who had a repeat positive polymerase chain reaction (PCR) test for SARS-CoV-2. We analyzed data of 22 COVID-19 patients who tested positive for SARS-CoV-2 on polymerase chain reaction (PCR) testing after two consecutive negative PCR results following discharge from hospitals. The interval between the two positive tests in the episodes of COVID-19 ranged from 4 to 117 days. More than one-third of the cases were healthcare workers (HCWs) and one-third of them had comorbidities. The main symptoms were cough and fever, and we noticed that males experienced more symptoms and signs of COVID-19 than females. Individuals with repeat SARS-CoV-2 positivity tend to experience milder illness during the second episode than the first episode. To confirm the reinfection of SARS-CoV-2, the results of other tests, such as viral culture and immunological assays of immunoglobulin G (IgG) and immunoglobulin M (IgM), need to be considered. Recovered COVID-19 patients should continue social distancing, using face masks, and practicing hand hygiene, especially HCWs who are more likely to be exposed to SARS-CoV-2.

SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature

Reinfection with SARS-CoV-2 seems to be a rare phenomenon. The objective of this study is to carry out a systematic search of literature on the SARS-CoV-2 reinfection in order to understand the success of the global vaccine campaigns. A systematic search was performed. Inclusion criteria included a positive RT-PCR test of more than 90 days after the initial test and the confirmed recovery or a positive RT-PCR test of more than 45 days after the initial test that is accompanied by compatible symptoms or epidemiological exposure, naturally after the confirmed recovery. Only 117 articles were included in the final review with 260 confirmed cases. The severity of the reinfection episode was more severe in 92/260 (35.3%) with death only in 14 cases. The observation that many reinfection cases were less severe than initial cases is interesting because it may suggest partial protection from disease. Another interesting line of data is the detection of different clades or lineages by genome sequencing between initial infection and reinfection in 52/260 cases (20%). The findings are useful and contribute towards the role of vaccination in response to the COVID-19 infections. Due to the reinfection cases with SARS-CoV-2, it is evident that the level of immunity is not 100% for all individuals. These data highlight how it is necessary to continue to observe all the prescriptions recently indicated in the literature in order to avoid new contagion for all people after healing from COVID-19 or becoming asymptomatic positive.

SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review

The world has been suffering from COVID-19 disease for more than a year, and it still has a high mortality rate. In addition to the need to minimize transmission of the virus through non-pharmacological measures such as the use of masks and social distance, many efforts are being made to develop a variety of vaccines to prevent the disease worldwide. So far, several vaccines have reached the final stages of safety and efficacy in various phases of clinical trials, and some, such as Moderna/NIAID and BioNTech/Pfizer, have reported very high safety and protection. The important point is that comparing different vaccines is not easy because there is no set standard for measuring neutralization. In this study, we have reviewed the common platforms of COVID-19 vaccines and tried to present the latest reports on the effectiveness of these vaccines.